Company: TLSA
Filing Date: 2025-02-18
Form Type: 6-K
Source: 0001213900-25-014594
Chunk: 0

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-02-18
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

February 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its
Charter)

9 thFloor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>

On February 18, 2025, Tiziana Life Sciences LTD (the “”)
issued this 6K announcing, the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA)
for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study (NCT06292923).
To date, 14 patients have now been enrolled in the expanded access program. The first 10 patients have all shown either an improvement
or stability of disease within 6 months of starting treatment., a copy of which is furnished as Exhibit 99.1

The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned